RNS Number : 8608A
Solgenics Limited
26 May 2023
 

Logo Description automatically generated

 

News Release

 

 

Result of GM

 

26 May 2023: Solgenics Limited ("Solgenics" or the "Company") (AIM: SGN) announces that, at the General Meeting ("GM") of the Company held today, the special resolutions to approve the cancellation of shares from AIM and to amend the Articles of Association were duly passed on a poll. The Company received authorised votes from 317,857,465 shares, representing 56% of the Company's shares in issue. Votes in support of both resolutions were 98% and 97% respectively.

 

The last day of dealings in the Company's Ordinary Shares on AIM will be Tuesday 6 June 2023 and the Cancellation will become effective at 7.00 a.m. on Wednesday 7 June 2023, subject to a dealing notice, as defined in the AIM Rules for Companies, being issued.

 

 

Enquiries

For further information please visit www.solgenics.com or contact:

Solgenics:

Hanno Pengilly

+27 (0) 71 362 3566

Liberum Capital Limited:
NOMAD & Joint Broker

 

Scott Mathieson, Edward Thomas, Kane Collings

+44 (0) 20 3100 2000

Novum Securities Limited

Joint Broker

Colin Rowbury

+44 (0) 20 7399 9427

 

Pimlico Advisory Ltd

Investor Relations

Elizabeth Johnson

+44 (0) 777 56 55 927

 

About Solgenics

Solgenics is an African renewable energy development company focused on the development of a 300MW solar PV plus BESS power project in the Tete Province in northern Mozambique (the "Tete Solar Project").

It is the intention that the Tete Solar Project will connect to the Mozambique grid with target power offtakers in Mozambique and the Southern African Power Pool ("SAPP").

The Tete Solar Project takes full advantage of Mozambique's leading sustainable energy resources and is fully aligned with Government's objective to become a champion for energy transition impacting all Southern Africa.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMFLFLSEDIRFIV